79561-25-4

Basic information

• Product Name: BOC-P-FLUORO-DL-PHE-OH
• Synonyms: BOC-P-FLUORO-DL-PHENYLALANINE;BOC-P-FLUORO-DL-PHE-OH;BOC-4-FLUORO-DL-PHENYLALANINE;BOC-DL-PHE(P-F)-OH;BOC-DL-PHE(4-F)-OH;BOC-DL-4-FLUOROPHENYLALANINE;N-T-BUTOXYCARBONYL-P-FLUORO-DL-PHENYLALANINE;(RS)-Boc-2-amino-3-(4-fluorophenyl)propionic acid
• CAS NO: 79561-25-4
• Molecular Formula: C₁₄H₁₈FNO₄
• Molecular Weight: 283.3
• Product Categories: Amino Acids
• Mol File: 79561-25-4.mol

Chemical Properties

• Boiling Point: 431.2 °C at 760 mmHg
• Flash Point: 214.6 °C
• Appearance: /
• Density: 1.216 g/cm³
• Vapor Pressure: 3.36E-08mmHg at 25°C
• Refractive Index: 1.517
• Storage Temp.: Store at RT.
• CAS DataBase Reference: BOC-P-FLUORO-DL-PHE-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-P-FLUORO-DL-PHE-OH(79561-25-4)
• EPA Substance Registry System: BOC-P-FLUORO-DL-PHE-OH(79561-25-4)

Safety Data

• Hazardous Substances Data: 79561-25-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
BOC-P-FLUORO-DL-PHE-OH is used as a building block for the production of peptide-based drugs or materials, providing unique properties and reactivity due to the fluorine substitution on the phenylalanine ring.
Used in Medicinal Chemistry:
BOC-P-FLUORO-DL-PHE-OH is used as a research compound for the development of new pharmaceuticals, leveraging its unique structure and properties to create innovative drug candidates.
Used in Materials Science:
BOC-P-FLUORO-DL-PHE-OH is used as a component in the design and synthesis of new materials with specific properties, such as improved stability or reactivity, for various applications.
Used in Biochemistry:
BOC-P-FLUORO-DL-PHE-OH is used in biochemical research to study the effects of fluorine substitution on the properties and interactions of amino acids, contributing to a better understanding of protein structure and function.

InChI:InChI=1/C14H18FNO4/c1-14(2,3)20-13(19)16-11(12(17)18)8-9-4-6-10(15)7-5-9/h4-7,11H,8H2,1-3H3,(H,16,19)(H,17,18)

Upstream product

• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 1132-68-9 L-4-fluorophenylalanine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 51-65-0 4-Fluorophenylalanine 
• 1534-90-3 D,L-4-fluorophenylalanine Ethyl Ester Hydrochloride 

Downstream Products

• 223526-61-2 ethyl-3->-E-propenoate 
• 1026975-73-4 (E)-(S)-4-[(S)-2-tert-Butoxycarbonylamino-3-(4-fluoro-phenyl)-propionylamino]-5-[(S)-1-(2,4-dimethoxy-benzyl)-2-oxo-piperidin-3-yl]-pent-2-enoic acid ethyl ester 
• 135545-01-6 tert-butyl N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[methoxy(methyl)amino]-2-oxo-ethyl]carbamate 
• 78981-74-5 N-EtPhe(4-F)-NH₂ 
• 78981-81-4 Boc-Gly-N-EtPhe(4-F)-NH₂ 
• 119745-73-2 [(S)-1-{(R)-1-[({[(S)-1-Carbamoyl-2-(4-fluoro-phenyl)-ethyl]-ethyl-carbamoyl}-methyl)-carbamoyl]-4-guanidino-butylcarbamoyl}-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 1226790-27-7 (3S)-6-bromo-2,3-dihydro-7-methyl-5-nitro-3-[Boc-L-4-fluorophenylalanyl]-1H-pyrrolo[1,2-a]benzimidazole 
• 1240522-49-9 (S)-2-amino-3-(4-fluorophenyl)-N-(1-methyl-3-(2-(methylamino)pyridin-4-yl)-1H-pyrazol-5-yl)propanamide 
• 1442476-55-2 (2S)-3-(4-fluorophenyl)-N-(3-(2-(methylamino)pyridin-4-yl)-1H-pyrazol-5-yl)-2-((thiazol-5-ylmethyl)amino)propanamide 
• 1240522-58-0 (S)-2-(((1H-1,2,3-triazol-4⁽⁵⁾-yl)methyl)amino)-3-(4-fluorophenyl)-N-(1-methyl-3-(2-(methylamino)pyridin-4-yl)-1H-pyrazol-5-yl)propanamide 
• 1240522-62-6 (2S)-2-((cyanomethyl)amino)-3-(4-fluorophenyl)-N-(1-methyl-3-(2-(methylamino)pyridin-4-yl)-1H-pyrazol-5-yl)propanamide 
• 1240522-59-1 2-((S)-3-(4-fluorophenyl)-1-(1-methyl-3-(2-(methylamino)pyridin-4-yl)-1H-pyrazol-5-ylamino)-1-oxopropan-2-ylamino)acetic acid 
• 1442476-60-9 C₂₁H₂₄FN₇O₂ 

Relevant articles and documents

Structure-Activity Relationships of cyclo(l -Tyrosyl- l -tyrosine) Derivatives Binding to Mycobacterium tuberculosis CYP121: Iodinated Analogues Promote Shift to High-Spin Adduct

A series of analogues of cyclo(l-tyrosyl-l-tyrosine), the substrate of the Mycobacterium tuberculosis enzyme CYP121, have been synthesized and analyzed by UV-vis and electron paramagnetic resonance spectroscopy and by X-ray crystallography. The introduction of iodine substituents onto cyclo(l-tyrosyl-l-tyrosine) results in sub-μM binding affinity for the CYP121 enzyme and a complete shift to the high-spin state of the heme FeIII. The introduction of halogens that are able to interact with heme groups is thus a feasible approach to the development of next-generation, tight binding inhibitors of the CYP121 enzyme, in the search for novel antitubercular compounds.

Design, Synthesis, and Pharmacokinetic Evaluation of Phosphate and Amino Acid Ester Prodrugs for Improving the Oral Bioavailability of the HIV-1 Protease Inhibitor Atazanavir

Phosphate and amino acid prodrugs of the HIV-1 protease inhibitor (PI) atazanavir (1) were prepared and evaluated to address solubility and absorption limitations. While the phosphate prodrug failed to release 1 in rats, the introduction of a methylene spacer facilitated prodrug activation, but parent exposure was lower than that following direct administration of 1. Val amino acid and Val-Val dipeptides imparted low plasma exposure of the parent, although the exposure of the prodrugs was high, reflecting good absorption. Screening of additional amino acids resulted in the identification of an l-Phe ester that offered an improved exposure of 1 and reduced levels of the circulating prodrug. Further molecular editing focusing on the linker design culminated in the discovery of the self-immolative l-Phe-Sar dipeptide derivative 74 that gave four-fold improved AUC and eight-fold higher Ctrough values of 1 compared with oral administration of the drug itself, demonstrating a successful prodrug approach to the oral delivery of 1.

NOVEL COMPOUNDS WITH DUAL ACTIVITY

The invention generally relate to novel compounds and uses thereof in preventing antifouling by unicellular organisms and in attracting cells from multicellular organisms.

Self-assembly of a tripeptide into a functional coating that resists fouling

This communication describes the self-assembly of a tripeptide into a functional coating that resists biofouling. Using this peptide-based coating we were able to prevent protein adsorption and interrupt biofilm formation. This coating can be applied on numerous substrates and therefore can serve in applications related to health care, marine and water treatment.

Antiretroviral hydrazine derivatives

The invention relates to compounds of formula STR1 and salts, pharmaceutical compositions, intermediates and processes of preparation thereof.

Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988

A study of structure-activity relationships of a series of 'dipeptoid' CCK-B receptor antagonists was performed in which variations of the phenyl ring were examined while the [(2-adamantyloxy)carbonyl]-α-methyl-R)-tryptophan moiety of the potent antagonist CI-988 was kept constant. Since the main focus of this study was phenyl substituent variation, series design techniques were employed to insure an adequate spread of physicochemical properties (lipophilic, steric, electronic), as well as positional substitution. A QSAR analysis on sets of 26 and 16 analogues revealed that CCK-B affinity was related to a combination of the overall size and, marginally, lipophilicity of the phenyl ring substituents (i.e., smaller groups were associated with increased potency with an optimum π near zero, respectively). Further exploration revealed that the dimensions and electronics of the para-phenyl substituent could be related to CCK-B affinity. Increased affinity was seen with short, bulky (branched) electron withdrawing groups. Analogs with small para-substituents appeared to be about 1000-fold CCK-B selective, indicating that selectivity for CCK-B binding is sensitive to phenyl ring substitution. The 4-F-phenyl dipeptoid, derived from this study, has extraordinary high affinity at the CCK-B receptor (IC50 = 0.08 nM) and was also very selective (940-fold CCK-B selective). Consistent with previous reports, (S)-configuration at the substituted phenethylamide center, a carboxylic acid and the presence of a phenyl ring were found to be associated with increased affinity at both CCK-A and CCK-B receptors.

Studies of Neurokinin Antagonists. 4. Synthesis and Structure-Activity Relationships of Novel Dipeptide Substance P Antagonists: N2--L-prolyl>-N-methyl-N-(phenylmethyl)-3-(2-naphthyl)-L-alaninamide and Its Related Compounds

As an extension of our studies on discovering a novel substance P (SP) antagonist, we modified the previously reported dipeptide, N2-2-(1H-indol-3-ylcarbonyl)-L-lysyl>-N-methyl-N-(phenylmethyl)-L-phenylalaninamide (2b).The lysine part in 2b was first optimized to a (2S,4R)-hydroxyproline derivative (3h), which is 2-fold more potent than 2b in SP binding assay using guinea pig lung membranes.Next we modified the 1H-indol-3-ylcarbonyl part in 3h.Introduction of a methyl group at the indole nitrogen enhanced the oral activity, while retaining the binding activity.Finally, we modified the phenylalanine part to culminate in the most potent compound 7k (FK888), which is a potent SP antagonist with NK1 selectivity as well as oral activity.